ARCH ready for big bets with new $400m venture fund

ARCH Venture Partners raised $400m for its eighth venture capital fund of which 50% to 75% is likely to be invested in biotechnology, including contributions to one or two big ideas for groundbreaking therapeutic platforms or other compelling opportunities.